Your Good Partner in Biology Research

  1. 首页
  2. 试剂盒
  3. 酶联免疫试剂盒
  4. Human Chromogranin,CgA ELISA Kit

Human Chromogranin,CgA ELISA Kit

  • 中文名称：
    人嗜铬蛋白A(CgA)酶联免疫试剂盒
  • 货号：
    CSB-E09153h
  • 规格：
    96T/48T
  • 价格：
    ￥3600/￥2500
  • 其他：

产品详情

  • 产品描述：

    This Human CHGA ELISA Kit was designed for the quantitative measurement of Human CHGA protein in serum, plasma, cell culture supernates, urine, cerebrospinal fluid (CSF). It is a Sandwich ELISA kit, its detection range is 62.5 ng/mL-4000 ng/mL and the sensitivity is 15.6 ng/mL.

  • 别名：
    beta Granin ELISA Kit; betagranin (N-terminal fragment of chromogranin A) ELISA Kit; catestatin ELISA Kit; CgA ELISA Kit; CHG A ELISA Kit; Chga ELISA Kit; chromofungin ELISA Kit; Chromogranin A ELISA Kit; Chromogranin A parathyroid secretory protein 1 ELISA Kit; Chromogranin A precursor ELISA Kit; ChromograninA ELISA Kit; CMGA_HUMAN ELISA Kit; ER-37 ELISA Kit; Pancreastatin ELISA Kit; Parastatin ELISA Kit; Parathyroid secretory protein 1 ELISA Kit; Pituitary secretory protein I ELISA Kit; Secretory protein I ELISA Kit; SP I ELISA Kit; SP-I ELISA Kit; SP1 ELISA Kit; SPI ELISA Kit; vasostatin 2 ELISA Kit; Vasostatin ELISA Kit; Vasostatin I ELISA Kit; Vasostatin II ELISA Kit; vasostatin-2 ELISA Kit
  • 缩写：
  • Uniprot No.：
  • 种属：
    Homo sapiens (Human)
  • 样本类型：
    serum, plasma, cell culture supernates, urine, cerebrospinal fluid (CSF)
  • 检测范围：
    62.5 ng/mL-4000 ng/mL
  • 灵敏度：
    15.6 ng/mL
  • 反应时间：
    1-5h
  • 样本体积：
    50-100ul
  • 检测波长：
    450 nm
  • 研究领域：
    Neuroscience
  • 测定原理：
    quantitative
  • 测定方法：
    Sandwich
  • 精密度：
    Intra-assay Precision (Precision within an assay): CV%<8%      
    Three samples of known concentration were tested twenty times on one plate to assess.  
    Inter-assay Precision (Precision between assays): CV%<10%      
    Three samples of known concentration were tested in twenty assays to assess.    
                 
  • 线性度：
    To assess the linearity of the assay, samples were spiked with high concentrations of human CgA in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
      Sample Serum(n=4)  
    1:1 Average % 86  
    Range % 83-89  
    1:2 Average % 102  
    Range % 97-107  
    1:4 Average % 106  
    Range % 102-110  
    1:8 Average % 97  
    Range % 95-99  
  • 回收率：
    The recovery of human CgA spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
    Sample Type Average % Recovery Range  
    Serum (n=5) 99 95-104  
    EDTA plasma (n=4) 94 90-98  
                 
                 
  • 标准曲线：
    These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
    ng/ml OD1 OD2 Average Corrected  
    4000 2.614 2.598 2.606 2.421  
    2000 2.054 2.078 2.066 1.881  
    1000 1.583 1.542 1.563 1.378  
    500 1.005 1.094 1.050 0.865  
    250 0.668 0.678 0.673 0.488  
    125 0.482 0.501 0.492 0.307  
    62.5 0.347 0.368 0.358 0.173  
    0 0.184 0.186 0.185    
  • 本试剂盒所含材料：
    • A micro ELISA plate ---The 96-well plate has been pre-coated with an anti-human CgA antibody. This dismountable microplate can be divided into 12 x 8 strip plates.
    • Two vials lyophilized standard ---Dilute a bottle of the standard at dilution series, read the OD values, and then draw a standard curve.
    • One vial Biotin-labeled CgA antibody (100 x concentrate) (120 μl/bottle) ---Act as the detection antibody.
    • One vial HRP-avidin (100 x concentrate) (120 μl/bottle) ---Bind to the detection antibody and react with the TMB substrate to make the solution chromogenic.
    • One vial Biotin-antibody Diluent (15 ml/bottle) ---Dilute the Biotin-antibody.
    • One vial HRP-avidin Diluent (15 ml/bottle) ---Dilute the HRP-avidin solution.
    • One vial Sample Diluent (50 ml/bottle)---Dilute the sample to an appropriate concentration.
    • One vial Wash Buffer (25 x concentrate) (20 ml/bottle) ---Wash away unbound or free substances.
    • One vial TMB Substrate (10 ml/bottle) ---Act as the chromogenic agent. TMB interacts with HRP, eliciting the solution turns blue.
    • One vial Stop Solution (10 ml/bottle) ---Stop the color reaction. The solution color immediately turns from blue to yellow.
    • Four Adhesive Strips (For 96 wells) --- Cover the microplate when incubation.
    • An instruction manual

    显示更多

    收起更多

  • 本试剂盒不含材料：
    • A microplate reader capable of measuring absorbance at 450 nm, with the correction wavelength set at 540 nm or 570 nm.
    • An incubator can provide stable incubation conditions up to 37°C±5°C.
    • Centrifuge
    • Vortex
    • Squirt bottle, manifold dispenser, or automated microplate washer
    • Absorbent paper for blotting the microtiter plate
    • 50-300ul multi-channel micropipette
    • Pipette tips
    • Single-channel micropipette with different ranges
    • 100ml and 500ml graduated cylinders
    • Deionized or distilled water
    • Timer
    • Test tubes for dilution

    显示更多

    收起更多

  • 数据处理：
  • 货期：
    3-5 working days

产品评价

靶点详情

  • 功能：
    Strongly inhibits glucose induced insulin release from the pancreas.; Inhibits catecholamine release from chromaffin cells and noradrenergic neurons by acting as a non-competitive nicotinic cholinergic antagonist. Displays antibacterial activity against Gram-positive bacteria S.aureus and M.luteus, and Gram-negative bacteria E.coli and P.aeruginosa. Can induce mast cell migration, degranulation and production of cytokines and chemokines. Acts as a potent scavenger of free radicals in vitro. May play a role in the regulation of cardiac function and blood pressure.; Regulates granule biogenesis in endocrine cells by up-regulating the transcription of protease nexin 1 (SERPINE2) via a cAMP-PKA-SP1 pathway. This leads to inhibition of granule protein degradation in the Golgi complex which in turn promotes granule formation.
  • 基因功能参考文献：
    1. Elevated serum CGA was negatively associated with overall survival in men with metastatic castrate resistant prostate cancer. Serum CGA represents a prognostic biomarker that may complement circulating tumor cells enumeration. PMID: 29858590
    2. Patients with higher catestatin levels developed worse ventricular function during the follow-up period. Single-point catestatin was effective to predict LVEDD change. And concurrently increasing catestatin and NT-proBNP levels predicted the highest risk of LV remodeling. This study suggests an important prognostic information of catestatin on LV remodeling. PMID: 28397784
    3. CgA and NSE are clinically valuable tumor markers in neuroblastoma and they merit prospective clinical evaluations as such. PMID: 29737901
    4. Vasostatin-1 is stably overexpressed in serum of patients with ileal and pancreatic neuroendocrine neoplasms. PMID: 29723285
    5. Results suggest that severe atopic dermatitis is associated with higher stress levels. Simple salivary CgA measurements may be useful as an objective assessment of patient stress. PMID: 28406540
    6. cardiac atria express but do not secrete CgA into circulation in patients with atrial disease PMID: 28685598
    7. These results suggest that circulating full-length CgA is an important inhibitor of angiogenesis and tumor growth, and that cleavage of its C-terminal region markedly reduces its activity. Pathophysiological changes in CgA blood levels and/or its fragmentation might regulate disease progression in cancer patients. PMID: 27683038
    8. Results show that chronic lymphocytic leukemia (CLL) patients had increased plasma levels of chromogranin A (CgA), compared to normal subjects, particularly those >70-year-old or those treated with proton pump inhibitors. PMID: 27203389
    9. The s show that CHGA-415 T/C polymorphism is an independent risk factor of poor prognosis in critically ill patients PMID: 28254729
    10. Concurrent increases in plasma BNP (B-type natriuretic peptide) and CST levels predicted the highest risk for both all-cause and cardiac deaths in chronic heart failure patients. PMID: 27771336
    11. Full-length CgA is an independent indicator of atherosclerotic plaques in carotid artery stenosis. PMID: 28190616
    12. Even a single baseline measurement of CgA can be useful in establishing prognosis in this group, if this parameter exceeds its upper normal limit more than tenfold. PMID: 28095720
    13. Compared with chromogranin A, chromogranin B may be more useful during proton pump inhibitor treatment and can detect tumors without liver metastases. PMID: 28334992
    14. Salivary impairments and high levels of CHGA are associated with T2DM patients. In addition, CGHA polymorphisms might be associated with salivary gland hypofunction and higher salivary CHGA production in T2DM patients. This could be a significant insight to establish a role for salivary CHGA as a potential clinical biomarker to T2DM. PMID: 26750135
    15. we could provide evidence that established stress-related biomarkers ET-1, MCP-1, CGA were differentially regulated among patients with AF compared to healthy controls. PMID: 28886122
    16. Combined plasma CgA concentrations and World Health Organization grading may assist in better stratification of PNET patients in terms of the risk of recurrence. PMID: 28043759
    17. Metastatic castration-resistant prostate cancer patients with an early high CGA rise may demonstrate a subgroup with poor outcome due to underlying small cell/neuroendocrine cell transformation. PMID: 28870943
    18. genetic association studies in population in India: Data suggest that common polymorphisms (SNPs) in CHGA promoter are associated with cardiometabolic disorders; c-Rel has a role in activating CHGA promoter haplotype 2 (variant T alleles at -1018 and -57 bp) under basal and pathophysiological conditions. (CHGA = chromogranin A; c-Rel = c-Rel proto-oncogene protein) PMID: 28667172
    19. Multivariate analyses of nonfunctional pancreatic neuroendocrine tumor patients with both grade and CgA recorded found poorly differentiated tumors and very high CgA negatively impacted survival. PMID: 28501118
    20. High chromogranin A expression is associated with neuroendocrine differentiation in colorectal cancer. PMID: 28351413
    21. Catestatin Gly364Ser Variant Alters Systemic Blood Pressure and the Risk for Hypertension in Human Populations via Endothelial Nitric Oxide Pathway. PMID: 27324226
    22. Plasma catestatin was associated with coronary collateral developments, suggesting a useful biomarker for coronary collateral development and potential target for therapeutic angiogenesis in patients with coronary artery chronic total occlusions (CTO). PMID: 27304618
    23. Increased myocardial CgA glycosylation and impaired CgA processing to catestatin in heart failure be considered detrimental because CST reduces diastolic Ca2+ leak via direct CaMKIIdelta inhibition. PMID: 28209766
    24. Data suggest pancreastatin, a 49 residue post-translational fragment of chromogranin A, as a routinely tested biomarker in neuroendocrine tumors (NETs) and in particular small bowel NET. PMID: 26684860
    25. Data indicate that measurement of chromogranin A (CgA) alone is sufficient in the management of patients with neuroendocrine tumours (NETs) and that routine additional measurement of chromogranin B (CgB) provides little added value. PMID: 26608723
    26. Data show that chrysin suppressed cell proliferation and reducing expression of achaete-scute complex-like 1 (ASCL1) and the neuroendocrine biomarker chromogranin A (CgA). PMID: 26403073
    27. In a Japanese population, the Ser-364 allele was associated with elevated systolic blood pressure and pulse pressure, consistent with increased arterial stiffness. PMID: 26211667
    28. ChrA levels were not effective in predicting outcomes or detecting recurrences of Merkel cell carcinoma. PMID: 26299616
    29. Decreased CSF levels of chromogranin A were found in Parkinson disease patients with orthostatic hypotension. PMID: 26359267
    30. In both mice and men the Gly364Ser polymorphism conferred metabolic traits such as elevated HDL and lowered norepinephrine levels; it was associated with superior baroreflex function and therefore better response to stress. PMID: 26556564
    31. In patients with resected pancreatic neuroendocrine tumors, an elevated preoperative CgA level was negatively associated with disease-free survival and overall survival. PMID: 26850182
    32. In astrocytes from multiple sclerosis white matter lesions the expression of chromogranin A is increased. PMID: 26683597
    33. Receiver operating characteristic analyses showed that ChgA autoantibodies are valuable in the predictive diagnosis of non-small cell lung cancer (NSCLC), suggesting that serum autoantibodies to ChgA-derived peptides are promising novel markers of NSCLC PMID: 26186986
    34. Diagnostic value of circulating chromogranin a for neuroendocrine tumors PMID: 25894842
    35. Data indicate that ADP-ribosylation factor 1 (Arf1) colocalizes with chromogranin A and regulates secretion of insulin like growth factor 1 (IGF-1) and is required for anchorage dependent growth. PMID: 25754106
    36. catestatin plays an important role in the progress of acute myocardial infarction PMID: 25848973
    37. The CHGA 3'-UTR C+87T disrupts an miR-107 motif, with differential effects on CHGA expression, and a cis:trans (mRNA:miR) interaction regulates the association of CHGA with BP and hypertensive nephropathy. PMID: 25392232
    38. Chromogranin A measurements are significantly assay-dependent and caution should be applied in the interpretation of CgA measurement for assessment of neuroendocrine tumor status. PMID: 25532001
    39. Chromogranin A (10-19) and chromogranin A (43-52) were identified as antigens for autoreactive CD8(+) T cells in Type 1 diabetes patients. PMID: 25958206
    40. Vasoconstriction-Inhibiting Factor (VIF), a degradation product of chromogranin A, is a vasoregulatory peptide that modulates the vasoconstrictive effects of angiotensin II by acting on the angiotensin II type 2 receptor. PMID: 25810338
    41. Patients with irritable bowel syndrome present a low density of CgA compared with controls. PMID: 25174455
    42. Report QT/heart rate variability in a genomically "humanized" chromogranin a monogenic mouse model with hyperadrenergic hypertension. PMID: 24821335
    43. Report fast and reliable measurement of chromogranin A with automated KRYPTOR assay. PMID: 25651748
    44. The study shows that chromogranin A is a useful marker for diagnosing pancreatic neuroendocrine tumors (pNET) in Japanese populations and for distinguishing patients with pNET from patients with other pancreatic diseases. PMID: 25220535
    45. reliable pathologic and circulating maker for diagnosis of gastroenteropancreatic neuroendocrine neoplasm PMID: 25501094
    46. a model to explain how the chromogranin A/Catecholamine complex governs the accumulation and exocytosis of secreted amines PMID: 25077558
    47. High serum Chromogranin A levels are associated with low response to chemotherapy in metastatic castration-resistant prostate cancer. PMID: 24741024
    48. Elevated plasma catestatin levels are predictive of malignant arrhythmia in patients with acute myocardial infarction. PMID: 24631953
    49. Letter: report diagnostic role of chromogranin A immunohistochemistry in hyalinizing trabecular tumor of the thyroid. PMID: 25012947
    50. High serum Chromogranin A levels are associated with pancreatic neuroendocrine tumors. PMID: 25099181

    显示更多

    收起更多

  • 亚细胞定位：
    [Serpinin]: Secreted. Cytoplasmic vesicle, secretory vesicle.; Cytoplasmic vesicle, secretory vesicle. Cytoplasmic vesicle, secretory vesicle, neuronal dense core vesicle. Secreted.
  • 蛋白家族：
    Chromogranin/secretogranin protein family
  • 组织特异性：
    GE-25 is found in the brain.
  • 数据库链接：

    HGNC: 1929

    OMIM: 118910

    KEGG: hsa:1113

    STRING: 9606.ENSP00000216492

    UniGene: Hs.150793